On July 8, Oruka Therapeutics rose 6.18% in regular trading, trading at $88.0/share, with turnover of $110 million.

On the news front, UBS Securities recently issued a research note stating that Oruka Therapeutics could further de-risk its lead psoriasis drug candidate, ORKA-001, with H2 data expected to demonstrate stronger 28-week efficacy than both its earlier 16-week results and AbbVie's Skyrizi. UBS expects the PASI100 response rate to increase from approximately 63% at week 16 to 70%-80% at week 28, noting that psoriasis treatments typically show improving efficacy over time.

UBS also highlighted that initial one-year durability data, expected in late Q3 or Q4, should provide an early indication of ORKA-001's potential for six-month or annual dosing. Additionally, the firm noted that AbbVie's planned acquisition of Apogee Therapeutics validates the underlying YTE platform technology used by Oruka. The company previously reported positive Phase 2a results in April showing 63.5% complete skin clearance at week 16 and secured a $700 million public offering to fund continued development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)